Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Minerva Neurosciences, Inc.NERV · Entity 6245 | Chief Business Officer and GC | April 21, 2026 | April 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Minerva Neurosciences, Inc.
Report date April 21, 2026 · Filed April 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.97 · Expires 2036-04-20 | Direct | 350,800 |
Reported balance
After 2026-04-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-21 · Grant · Acquired 350,800 · Balance 350,800 F1: The option vests 25% on April 21, 2027 and then in equal quarterly installments over 3 years thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests 25% on April 21, 2027 and then in equal quarterly installments over 3 years thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 21, 2026 Filed Apr 22, 2026 20:55 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantEmployee Stock Option (right to buy) · Derivative | 350,800 | $0.00 Strike: $6.97 | $0.00 |
DisclosureSEC source: 0002129698-26-000004 · form4-04222026_080414.xml · derivative · entry 1 O'Connor James Joseph · CIK 0002129698 · Chief Business Officer and GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,800 Underlying: Common Stock · 350,800 shares Expires 2036-04-20 F1 · derivative.exercise_date: The option vests 25% on April 21, 2027 and then in equal quarterly installments over 3 years thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.